Key takeaways
- Tirzepatide reduced major adverse cardiovascular events (MACE) by 33% compared to sitagliptin in a large clinical study.
A large clinical study has revealed that Eli Lilly's blockbuster GLP-1 medication, tirzepatide (sold under the brand name Mounjaro), substantially reduces the risk of major adverse cardiovascular events (MACE) in a critical patient group.
As reported in a medical study analysis highlighted by financial and investment research forum The Motley Fool, the data shows that tirzepatide reduces the combined risk of heart attacks, strokes, and all-cause mortality by approximately 33% when compared to sitagliptin, an older daily oral medication used to manage type 2 diabetes.
These findings add to a growing mountain of clinical evidence demonstrating that modern GLP-1 receptor agonists do far more than just lower blood sugar and promote weight loss. For millions of Americans living with chronic metabolic and cardiovascular conditions, these drugs are increasingly being recognized as foundational tools for long-term heart health.
The Key Numbers Behind the Study
The study evaluated the cardiovascular outcomes of patients who have both type 2 diabetes and pre-existing heart disease. Researchers tracked the occurrence of MACE—defined as heart attacks, strokes, and death from any cause—over the course of one year.
The clinical outcomes revealed a significant gap between the two treatment groups:
- The Tirzepatide Group: After one year, patients taking tirzepatide had a 2.9% risk of experiencing a major adverse cardiovascular event.
- The Sitagliptin Group: Patients taking the comparator drug, sitagliptin, experienced a 4.4% risk of MACE over the same timeframe.
- Absolute Impact: Researchers calculated that for every 70 patients who initiate treatment with tirzepatide, one case of MACE is actively prevented within the first year of therapy.
By achieving a 33% relative risk reduction over an established diabetes treatment like sitagliptin, tirzepatide solidifies its status as a highly protective therapy for high-risk patients.
What is Tirzepatide?
Tirzepatide is a dual GIP and GLP-1 receptor agonist. Unlike older single-hormone medications like semaglutide (the active ingredient in Ozempic and Wegovy), tirzepatide targets two different gut hormone pathways to regulate appetite, improve insulin sensitivity, and slow digestion.
To learn more about how these two leading clinical compounds compare, read our detailed breakdown of semaglutide vs. tirzepatide.
Currently, Eli Lilly markets tirzepatide under two brand names in the United States:
- Mounjaro: FDA-approved specifically for the treatment of type 2 diabetes.
- Zepbound: FDA-approved specifically for chronic weight management in patients with obesity or overweight and at least one weight-related comorbidity.
Both brand-name medications contain the exact same active ingredient (tirzepatide) and are administered via weekly subcutaneous injections.
Why This Matters for US GLP-1 Shoppers
For years, many health insurance providers in the United States viewed weight-loss medications as "lifestyle" drugs, often excluding them from standard employer-sponsored formularies. This new cardiovascular data is part of a broader clinical shift that is forcing insurers to rethink coverage.
1. Stronger Case for Insurance Coverage
Insurance companies are far more likely to cover expensive medications when they are proven to prevent costly, life-threatening emergency events like heart attacks and strokes. If you have type 2 diabetes and a history of cardiovascular disease, this data provides your healthcare provider with powerful ammunition to appeal insurance denials or secure prior authorizations. For more information on navigating these hurdles, see our guide on what insurance covers GLP-1 medications.
2. Choosing Between Medications
If you are currently deciding between different medical weight-loss options, such as Wegovy vs. Zepbound, cardiovascular protection is a major variable to discuss with your doctor. While Wegovy (semaglutide) already carries an FDA approval for reducing cardiovascular risk in adults with heart disease and obesity, this new data suggests that tirzepatide is building an equally compelling case for heart health.
3. Rise of Telehealth and Compounded Alternatives
Because brand-name Mounjaro and Zepbound can cost upwards of $1,000 per month out-of-pocket without insurance, many Americans are turning to online healthcare providers. Through telehealth, patients can access licensed physicians, undergo virtual consultations, and obtain prescriptions for either brand-name medications or compounded formulations.
During ongoing supply shortages, compounded tirzepatide has become an increasingly popular option for patients who cannot find or afford commercial brand-name pens. If you are exploring these alternative options, you can research the differences in our analysis of compounded vs. brand-name semaglutide and tirzepatide.
Finding the Right Provider
If you are interested in exploring tirzepatide for weight loss, diabetes management, or overall metabolic health, online medical weight-loss platforms offer a convenient starting point. These platforms connect you with licensed US clinicians who can evaluate your health history, order necessary lab work, and prescribe the appropriate therapy.
To compare current platforms, monthly program fees, and medication availability, visit our interactive provider comparison tool. If you are ready to match with a platform tailored to your budget and insurance status, you can complete our brief provider questionnaire.
Disclaimer: CompareRx does not provide medical advice. This article is for informational purposes only. GLP-1 medications, including tirzepatide, carry potential side effects and risks. Always consult with a licensed healthcare professional before starting or changing any medication regimen.